Literature DB >> 17981003

Opioid-induced bowel dysfunction.

Jay Thomas1.   

Abstract

Opioid-induced bowel dysfunction is a distressing condition that may persist indefinitely in the clinical setting. As we understand more about normal gastrointestinal (GI) physiology, we are also beginning to understand more fully how opioids cause bowel dysfunction. Current therapeutic interventions for opioid-induced bowel dysfunction can be burdensome and sometimes lack efficacy. Systemic opioid antagonists administered orally can induce laxation, but can unpredictably induce systemic or local GI tract withdrawal symptoms. Two new investigational agents, alvimopan and methylnaltrexone, are peripherally acting opioid antagonists that do not cross the blood-brain barrier. Studies to date show promise that these agents may relieve opioid-induced bowel dysfunction in a well-tolerated manner without reversing central analgesia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17981003     DOI: 10.1016/j.jpainsymman.2007.01.017

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  25 in total

Review 1.  Evolving paradigms in the treatment of opioid-induced bowel dysfunction.

Authors:  Jakob Lykke Poulsen; Christina Brock; Anne Estrup Olesen; Matias Nilsson; Asbjørn Mohr Drewes
Journal:  Therap Adv Gastroenterol       Date:  2015-11       Impact factor: 4.409

Review 2.  Central nervous system control of gastrointestinal motility and secretion and modulation of gastrointestinal functions.

Authors:  Kirsteen N Browning; R Alberto Travagli
Journal:  Compr Physiol       Date:  2014-10       Impact factor: 9.090

3.  Concomitant Opioid and Laxative Use in Older Adults in Hospice Care in the United States: 2007.

Authors:  Denys T Lau; Lisa L Dwyer; Joseph W Shega
Journal:  J Am Geriatr Soc       Date:  2016-09-19       Impact factor: 5.562

Review 4.  Pharmacological challenges in chronic pancreatitis.

Authors:  Anne Estrup Olesen; Anne Brokjaer; Iben Wendelboe Fisher; Isabelle Myriam Larsen
Journal:  World J Gastroenterol       Date:  2013-11-14       Impact factor: 5.742

5.  Differences in the characteristics of tolerance to μ-opioid receptor agonists in the colon from wild type and β-arrestin2 knockout mice.

Authors:  Hercules T Maguma; William L Dewey; Hamid I Akbarali
Journal:  Eur J Pharmacol       Date:  2012-04-11       Impact factor: 4.432

6.  Association between initial morphine intake and body weight change, acoustic startle reflex and drug seeking in rats.

Authors:  Thien Le; Mercedes Xia; Min Jia; Nathan Sarkar; Jerry Chen; He Li; Gary H Wynn; Robert J Ursano; Kwang H Choi
Journal:  Psychopharmacology (Berl)       Date:  2014-05-13       Impact factor: 4.530

7.  Managing opioid-induced constipation in advanced illness: focus on methylnaltrexone bromide.

Authors:  Katri Elina Clemens; Eberhard Klaschik
Journal:  Ther Clin Risk Manag       Date:  2010-03-03       Impact factor: 2.423

Review 8.  [Methylnaltrexone. A new approach for therapy of opioid-induced obstipation].

Authors:  D Chappell; P Conzen
Journal:  Schmerz       Date:  2009-10       Impact factor: 1.107

9.  Opioid-induced constipation reversal in response to placebo in a patient with a history of IBS receiving methadone maintenance therapy.

Authors:  Andriy V Samokhvalov; Jürgen Rehm
Journal:  BMJ Case Rep       Date:  2015-11-13

Review 10.  Opioid-induced bowel dysfunction: pathophysiology and management.

Authors:  Christina Brock; Søren Schou Olesen; Anne Estrup Olesen; Jens Brøndum Frøkjaer; Trine Andresen; Asbjørn Mohr Drewes
Journal:  Drugs       Date:  2012-10-01       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.